Treace Medical Concepts Inc (TMCI)

$5.43

+0.65

(+13.6%)

Market is closed - opens 8 PM, 05 Nov 2024

Performance

  • $4.70
    $5.58
    $5.43
    downward going graph

    13.44%

    Downside

    Day's Volatility :15.77%

    Upside

    2.69%

    downward going graph
  • $3.92
    $15.98
    $5.43
    downward going graph

    27.81%

    Downside

    52 Weeks Volatility :75.47%

    Upside

    66.02%

    downward going graph

Returns

PeriodTreace Medical Concepts IncSector (Health Care)Index (Russel 2000)
3 Months
-24.49%
-2.1%
0.0%
6 Months
-57.36%
4.9%
0.0%
1 Year
-55.9%
16.0%
0.0%
3 Years
-80.27%
10.0%
-26.4%

Highlights

Market Capitalization
297.9M
Book Value
$1.80
Earnings Per Share (EPS)
-1.02
Wall Street Target Price
6.88
Profit Margin
-32.08%
Operating Margin TTM
-48.1%
Return On Assets TTM
-17.02%
Return On Equity TTM
-48.6%
Revenue TTM
198.5M
Revenue Per Share TTM
3.21
Quarterly Revenue Growth YOY
6.0%
Gross Profit TTM
114.3M
EBITDA
-57.9M
Diluted Eps TTM
-1.02
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.94
EPS Estimate Next Year
-0.77
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Treace Medical Concepts Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 26.7%

Current $5.43
Target $6.88

Company Financials

FY19Y/Y Change
Revenue
39.4M
-
Net Income
-5.1M
-
Net Profit Margin
-12.95%
-
FY20Y/Y Change
Revenue
57.4M
↑ 45.54%
Net Income
-6.4M
↑ 26.22%
Net Profit Margin
-11.24%
↑ 1.71%
FY21Y/Y Change
Revenue
94.4M
↑ 64.59%
Net Income
-24.6M
↑ 281.88%
Net Profit Margin
-26.07%
↓ 14.83%
FY22Y/Y Change
Revenue
141.8M
↑ 50.22%
Net Income
-47.3M
↑ 92.17%
Net Profit Margin
-33.35%
↓ 7.28%
FY23Y/Y Change
Revenue
187.1M
↑ 31.92%
Net Income
-49.5M
↑ 4.71%
Net Profit Margin
-26.47%
↑ 6.88%
Q1 FY23Q/Q Change
Revenue
42.2M
↓ 15.22%
Net Income
-13.1M
↑ 275.74%
Net Profit Margin
-31.12%
↓ 24.1%
Q2 FY23Q/Q Change
Revenue
42.0M
↓ 0.57%
Net Income
-12.3M
↓ 6.56%
Net Profit Margin
-29.25%
↑ 1.87%
Q3 FY23Q/Q Change
Revenue
40.8M
↓ 2.85%
Net Income
-17.5M
↑ 42.78%
Net Profit Margin
-42.99%
↓ 13.74%
Q4 FY23Q/Q Change
Revenue
62.2M
↑ 52.64%
Net Income
-6.3M
↓ 64.15%
Net Profit Margin
-10.1%
↑ 32.89%
Q1 FY24Q/Q Change
Revenue
51.1M
↓ 17.85%
Net Income
-18.7M
↑ 197.34%
Net Profit Margin
-36.54%
↓ 26.44%
Q2 FY24Q/Q Change
Revenue
44.5M
↓ 13.02%
Net Income
-21.2M
↑ 13.55%
Net Profit Margin
-47.7%
↓ 11.16%
FY19Y/Y Change
Total Assets
29.7M
-
Total Liabilities
26.6M
-
FY20Y/Y Change
Total Assets
41.8M
↑ 40.69%
Total Liabilities
41.0M
↑ 54.51%
FY21Y/Y Change
Total Assets
140.8M
↑ 236.84%
Total Liabilities
47.7M
↑ 16.37%
FY22Y/Y Change
Total Assets
159.0M
↑ 12.93%
Total Liabilities
98.5M
↑ 106.28%
FY23Y/Y Change
Total Assets
251.9M
↑ 58.41%
Total Liabilities
114.0M
↑ 15.71%
Q1 FY23Q/Q Change
Total Assets
249.2M
↑ 56.69%
Total Liabilities
91.6M
↓ 7.05%
Q2 FY23Q/Q Change
Total Assets
249.6M
↑ 0.19%
Total Liabilities
99.7M
↑ 8.88%
Q3 FY23Q/Q Change
Total Assets
240.4M
↓ 3.72%
Total Liabilities
102.5M
↑ 2.82%
Q4 FY23Q/Q Change
Total Assets
251.9M
↑ 4.8%
Total Liabilities
114.0M
↑ 11.19%
Q1 FY24Q/Q Change
Total Assets
242.7M
↓ 3.64%
Total Liabilities
116.3M
↑ 2.08%
Q2 FY24Q/Q Change
Total Assets
226.1M
↓ 6.86%
Total Liabilities
113.9M
↓ 2.06%
FY19Y/Y Change
Operating Cash Flow
-7.7M
-
Investing Cash Flow
-1.2M
-
Financing Cash Flow
19.7M
-
FY20Y/Y Change
Operating Cash Flow
-4.5M
↓ 41.43%
Investing Cash Flow
-1.1M
↓ 11.73%
Financing Cash Flow
11.5M
↓ 41.72%
FY21Y/Y Change
Operating Cash Flow
-17.2M
↑ 282.58%
Investing Cash Flow
-2.7M
↑ 153.04%
Financing Cash Flow
107.7M
↑ 835.86%
FY22Y/Y Change
Operating Cash Flow
-30.6M
↑ 78.26%
Investing Cash Flow
-76.5M
↑ 2728.76%
Financing Cash Flow
20.8M
↓ 80.67%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.3M
↑ 222.12%
Investing Cash Flow
-80.5M
↑ 25.73%
Financing Cash Flow
107.9M
↑ 36222.9%
Q2 FY23Q/Q Change
Operating Cash Flow
-8.3M
↓ 51.71%
Investing Cash Flow
-10.4M
↓ 87.05%
Financing Cash Flow
1.2M
↓ 98.91%

Technicals Summary

Sell

Neutral

Buy

Treace Medical Concepts Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Treace Medical Concepts Inc
Treace Medical Concepts Inc
-10.49%
-57.36%
-55.9%
-80.27%
-81.28%
Stryker Corporation
Stryker Corporation
4.54%
12.8%
32.62%
35.95%
78.95%
Boston Scientific Corp.
Boston Scientific Corp.
-1.09%
15.26%
58.34%
96.75%
104.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.13%
-20.63%
0.66%
-42.46%
-13.89%
Abbott Laboratories
Abbott Laboratories
5.29%
12.27%
24.84%
-8.13%
44.25%
Medtronic Plc
Medtronic Plc
2.05%
10.16%
22.68%
-25.37%
-15.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Treace Medical Concepts Inc
Treace Medical Concepts Inc
NA
NA
NA
-0.94
-0.49
-0.17
NA
1.8
Stryker Corporation
Stryker Corporation
38.19
38.19
2.49
12.05
0.19
0.07
0.01
52.87
Boston Scientific Corp.
Boston Scientific Corp.
69.44
69.44
1.53
2.46
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
28.62
28.62
6.15
2.53
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
36.05
36.05
2.2
4.67
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.05
30.05
1.65
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Treace Medical Concepts Inc
Treace Medical Concepts Inc
Buy
$297.9M
-81.28%
NA
-32.08%
Stryker Corporation
Stryker Corporation
Buy
$138.5B
78.95%
38.19
16.34%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$123.7B
104.05%
69.44
11.26%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.7B
-13.89%
28.62
65.86%
Abbott Laboratories
Abbott Laboratories
Buy
$205.7B
44.25%
36.05
13.99%
Medtronic Plc
Medtronic Plc
Buy
$116.1B
-15.94%
30.05
12.06%

Insights on Treace Medical Concepts Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 62.21M → 44.45M (in $), with an average decrease of 15.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -6.28M → -21.20M (in $), with an average decrease of 105.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 59.2% return, outperforming this stock by 115.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 96.8% return, outperforming this stock by 177.1%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    9.10%
  • Armistice Capital, LLC

    8.62%
  • BlackRock Inc

    6.54%
  • William Blair Investment Management, LLC

    5.92%
  • Vanguard Group Inc

    5.83%
  • Soleus Capital Management, L.P.

    3.80%

Company Information

treace medical concepts, inc. is a privately-funded, commercial stage company focused on bringing breakthrough technologies to the high-growth $1.1 billion us market for foot and ankle surgical products. we are committed to operating our business with the highest standards of ethical conduct. we will exceed our customers’ expectations through an innovation-driven, high-velocity approach to solving treatment and surgical problems. with our products and services, our mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for our employees and an exceptional return for our shareholders.

Organization
Treace Medical Concepts Inc
Employees
516
CEO
Mr. John T. Treace
Industry
Healthcare

FAQs